

Yetter Wayne P.
Form 4
August 27, 2009

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Yetter Wayne P.

2. Issuer Name and Ticker or Trading Symbol
NOVEN PHARMACEUTICALS INC [NOVN]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2009

Director 10% Owner
 Officer (give title below) Other (specify below)

C/O NOVEN PHARMACEUTICALS, INC., 11960 SW 144TH STREET

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

MIAMI, FL 33186

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D)	Price		
				Code	V	Amount	
Common Stock (\$0.0001 par value)	08/27/2009		D	D	\$ 16.50	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Edgar Filing: Yetter Wayne P. - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Stock Option (Right to Buy)	\$ 19.66	08/27/2009		D ⁽¹⁾	12,500	⁽¹⁾ 08/06/2011	Common Stock (\$0.0001 par value)	12,500
Stock Option (Right to Buy)	\$ 21.15	08/27/2009		D ⁽¹⁾	5,000	⁽¹⁾ 05/14/2012	Common Stock (\$0.0001 par value)	5,000
Stock Option (Right to Buy)	\$ 9.74	08/27/2009		D ⁽²⁾	5,000	⁽²⁾ 05/13/2013	Common Stock (\$0.0001 par value)	5,000
Stock Option (Right to Buy)	\$ 11.3	08/27/2009		D ⁽³⁾	2,500	⁽³⁾ 08/04/2013	Common Stock (\$0.0001 par value)	2,500
Stock Option (Right to Buy)	\$ 18.73	08/27/2009		D ⁽¹⁾	7,500	⁽¹⁾ 05/17/2014	Common Stock (\$0.0001 par value)	7,500
Stock Option (Right to Buy)	\$ 17.41	08/27/2009		D ⁽¹⁾	7,500	⁽¹⁾ 05/23/2015	Common Stock (\$0.0001 par value)	7,500

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Yetter Wayne P. C/O NOVEN PHARMACEUTICALS, INC. 11960 SW 144TH STREET MIAMI, FL 33186	X			

Signatures

/s/ Wayne P.
Yetter

08/27/2009

__Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Represents stock options cancelled at the Effective Time (as defined in the Merger Agreement), pursuant to the terms of an Agreement and Plan of Merger among the Issuer, Hisamitsu Pharmaceutical Co., Inc. ("Hisamitsu") and certain subsidiaries of Hisamitsu, dated as of July 14, 2009 (the "Merger Agreement"). The reporting person did not receive any cash payment therefor as the exercise price exceeded the tender offer price of \$16.50.

(2) Represents stock options cancelled at the Effective Time, pursuant to the Merger Agreement, in exchange for a cash payment of \$33,800, representing the number of shares of Issuer's common stock underlying such options multiplied by the tender offer price of \$16.50 per share, less the aggregate exercise price of the options.

(3) Represents stock options cancelled at the Effective Time, pursuant to the Merger Agreement, in exchange for a cash payment of \$13,000, representing the number of shares of Issuer's common stock underlying such options multiplied by the tender offer price of \$16.50 per share, less the aggregate exercise price of the options.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.